We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.11B
AUM Growth
-$139M
Cap. Flow
-$141M
Cap. Flow %
-12.73%
Top 10 Hldgs %
67.11%
Holding
44
New
8
Increased
11
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$36M
2
CYTK icon
Cytokinetics
CYTK
+$24.1M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$14.5M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$13.6M
5
XENT
Intersect ENT, Inc
XENT
+$13.5M

Top Sells

Rank Stock Value
1
AKBA icon
Akebia Therapeutics
AKBA
+$47.7M
2
TGTX icon
TG Therapeutics
TGTX
+$39.6M
3
ZYME icon
Zymeworks
ZYME
+$34.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$26.6M
5
NXTC icon
NextCure
NXTC
+$21.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALA
26
DELISTED
Calithera Biosciences, Inc
CALA
$10.1M 0.91%
145,929
+32,844
+29% +$2.87M
KDMN
27
DELISTED
Kadmon Holdings, Inc.
KDMN
$9.8M 0.88%
2,500,000
+1,824,321
+270% +$7.66M
VRAY
28
DELISTED
ViewRay, Inc.
VRAY
$9.29M 0.84%
2,655,763
-118,048
-4% -$329K
LNTH icon
29
Lantheus
LNTH
$6.49B
$7.54M 0.68%
+594,750
New +$8.16M
LQDA icon
30
Liquidia Corp
LQDA
$7.48B
$5.85M 0.53%
1,189,607
-88,348
-7% -$511K
CYTK icon
31
PUT
Cytokinetics
CYTK
$10.5B
$5.48M 0.49%
+253,000
New +$5.92M
ABEO icon
32
Abeona Therapeutics
ABEO
$366M
$3.97M 0.36%
155,717
-132,803
-46% -$8.37M
TPST icon
33
Tempest Therapeutics
TPST
$13.7M
$1.92M 0.17%
6,041
-1,450
-19% -$492K
OYST
34
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.48M 0.13%
70,121
-144,510
-67% -$3.38M
AKBA icon
35
Akebia Therapeutics
AKBA
$354M
– –
-3,510,073
Closed -$47.7M
ARVN icon
36
CALL
Arvinas
ARVN
$518M
– –
-203,500
Closed -$6.83M
CTMX icon
37
CytomX Therapeutics
CTMX
$675M
– –
-1,448,604
Closed -$12.1M
DNLI icon
38
Denali Therapeutics
DNLI
$3.65B
– –
-280,000
Closed -$6.77M
NGNE icon
39
Neurogene
NGNE
$656M
– –
-703
Closed -$233K
NXTC icon
40
NextCure
NXTC
$16.9M
– –
-83,306
Closed -$21.4M
PTCT icon
41
PTC Therapeutics
PTCT
$5.68B
– –
-330,000
Closed -$16.7M
AXNX
42
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-459,503
Closed -$16.1M
MTEM
43
DELISTED
Molecular Templates, Inc.
MTEM
– –
-89,693
Closed -$18.6M
XLRN
44
DELISTED
Acceleron Pharma
XLRN
– –
-58,056
Closed -$5.53M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Great Point Partners held 44 positions worth $1.11B, down 11% from $1.25B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Great Point Partners withdrew a net $141M in Q3 2020, closing 10 positions and reducing 15 holdings. Its most notable exit was Akebia Therapeutics, an estimated $47.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Aurinia Pharmaceuticals worth $36.6M.

  • Great Point Partners's largest Q3 2020 buy was Aurinia Pharmaceuticals: 2,485,327 shares worth $36.6M.
  • Great Point Partners added most to Cytokinetics in Q3 2020, an estimated $24.1M increase.
  • Great Point Partners's biggest Q3 2020 reduction was TG Therapeutics, cutting an estimated $39.6M.
  • Great Point Partners fully exited Akebia Therapeutics in Q3 2020, selling an estimated $47.7M.
  • Great Point Partners's ten largest holdings make up 67% of its $1.11B portfolio in Q3 2020.
  • Great Point Partners opened 8 new positions and closed 10 in Q3 2020.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $1.11B.

Based on Great Point Partners's 13F filing for Q3 2020, filed 16 Nov 2020.